Fundraising Fox3E Bioventures Capital — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
OncoImmuneoncoimmune.comJan 2017 · $56M
First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.
BiotechRockville, US
Pan Zheng(Executive Officer)Yang Liu(Executive Officer, Director)Martin Devenport(Executive Officer)
BoardMiao Hong(Director)Karen Liu(Director)inKun-Liang Guan(Director)
Co-investorsHM Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.